Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | THRA | P10827 | 3/20 | 0.51 |
| ▸ | THRB | P10828 | 3/20 | 0.51 |
| ▸ | FBP1 | P09467 | 7/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487758 | 0.89 | PPARA (0.56) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL5813916 | 0.86 | MAOA (0.49) | MAOATHRATHRBKDRHDAC1 | |
| SCHEMBL2668321 | 0.82 | MAOA (0.50) | MAOATHRATHRBHDAC1 | |
| SCHEMBL4665845 | 0.77 | PDE3B (0.55) | PPARACYP1A2CYP3A4MAOATHRA | |
| SCHEMBL3791624 | 0.76 | MAOA (0.48) | CYP1A2CYP3A4MAOAHDAC1 | |
| SCHEMBL27623659 | 0.76 | MAOA (0.59) | MAOAHDAC1 | |
| SCHEMBL30621292 | 0.76 | MAOA (0.59) | MAOAHDAC1 | |
| SCHEMBL15580691 | 0.75 | PPARA (0.67) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL11548436 | 0.75 | PPARA (0.76) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3903999 | 0.75 | PPARA (0.76) | PPARAABCB11CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203151-A1 | Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions | KALYPSYS, INC. (US) | 2005-09-15 | — | — | US | disclosed |
| WO-2005060958-A1 | (5- (2-PHENYL)-THIAZOL-5-YLMETHOXY)-INDOL-1-YL) -ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE HUMAN PPAR-DELTA RECEPTOR FOR THE TREATMENT OF METABOLIC DISORDERS SUCH AS TYPE 2 DIABETES | KALYPSYS, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203151-A1 | Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions | PPARG, PPARD, PPARA | PPARA 3/4885ABCB11 1648/4885CYP1A2 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.